Immix Biopharma, Inc.
NXC-201
Countdown
86days
Phase 2 readout · ~ Sep 30, 2026 estimated
What's at stake
Phase 2 trial results for NXC-201 in its lead indication are due ~ Sep 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 12h ago
“with topline results expected in Q3 2026.”